Abstract: An engine includes a cylinder head and a cylinder block. The cylinder head has a first water jacket passage, an exhaust passage and a second water jacket passage. The exhaust passage is located between the first water jacket passage and the second water jacket passage. The first water jacket passage and the second water jacket passage are disposed close to the exhaust passage. The first water jacket passage is in communication with the second water jacket passage. The second water jacket passage is in communication with the cylinder block. The second water jacket passage has a water inlet passage.

Abstract: An engine includes an engine water jacket, a water pump and a thermostat assembly. The engine water jacket, the thermostat assembly and the water pump are connected to form a circulation passage. The thermostat assembly is connected between the engine water jacket and the water pump. The engine water jacket includes a cylinder head water jacket and a cylinder block water jacket. The thermostat assembly is configured to enable the coolant to enter the cylinder head water jacket of the cylinder head water jacket and the cylinder block water jacket upon cold start.

Abstract: A charger including a vertical section including a first surface, the first surface facing a front direction and including an attachment portion configured to a receive a battery pack, and a horizontal section configured to protrude, in the front direction, from a bottom portion of the vertical section. The charger further including a second surface disposed on the horizontal section, the second surface facing an upward direction, and a fan disposed proximate the horizontal surface, the fan configured to cool the battery pack.

Abstract: An engine includes a cylinder block, a cylinder head, and a piston. The cylinder head is connected to the cylinder block. The piston is movably connected to the cylinder block. The cylinder block, the cylinder head, and the piston form a combustion chamber. The cylinder head includes an intake valve hole and an exhaust valve hole. An intake valve is disposed at the intake valve hole and an exhaust valve is disposed at the exhaust valve hole. A barrier protrusion is protruded at the edge of the intake valve hole away from the exhaust valve hole. The included angle between a first connecting line connecting a first end of the barrier protrusion and a center of the intake valve hole and a second connecting line connecting a second end of the barrier protrusion and the center of the intake valve hole is greater than 120 degrees and less than or equal to 180 degrees.

Abstract: A JAK inhibitor may be used in preparation of a medicament. The medicament may be used for preventing and/or treating a disease or condition associated with an antitumor agent in a subject. A pharmaceutical composition may include the JAK inhibitor as may a kit. The JAK inhibitor may include a compound of formula (I) or a pharmaceutically acceptable salt thereof: Q, X, Y, and Z being independently N or C, and R1, R2 and R3 being independently a 5-6-membered aromatic ring, 5-6-membered heteroaromatic ring, 5-6-membered cycloalkyl, 5-6-membered heterocycloalkyl, amino, or amido, the aromatic ring, heteroaromatic ring, cycloalkyl, and/or heterocycloalkyl being optionally substituted by a substituent.

Abstract: A flexible adaptive large length to thin ratio pipeline intelligent repair device is provided. The walking mechanism includes a walking bracket and a radius adjustment assembly. The radius adjustment assembly is located in the middle of the walking bracket. The first motor for driving the radius adjustment assembly is set in the middle of the walking mechanism, and the second motor for driving the movement of the walking bracket is set on the walking bracket. The ends of several groups of connecting rods are removably connected to the working part, which includes the pre-welding sandblasting mechanism, the heating mechanism and the welding repair mechanism. A positioning sensor is set on the walking bracket. The variable-diameter all-position intelligent pipe internal repair device can integrate pre-welding cleaning, preheating, welding repair and post-welding heat treatment.

Abstract: The present application relates to a thymidine derivative, or use of a uridine derivative in combination with a thymidine derivative in preparation of a drug for preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject. The present application further provides a method of preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject comprising administering a prophylactically or therapeutically effective amount of a thymidine derivative or uridine and thymidine derivatives to a subject in need thereof.

Abstract: A power margin tracking control method and system for a multi-terminal high-voltage direct current converter station are provided. A power adjustment factor is introduced on the basis of a droop coefficient, to realize a self-adaptive regulation of a converter station operation mode to a real-time fluctuation of a wind and solar power. In this way, the system operation stability and the power fluctuation allocation capability in a grid-connected system are improved. Furthermore, a DC voltage deviation in the multi-terminal high-voltage direct current grid is reduced.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: The present disclosure relates to complexes comprising caffeine and tannic acid as well as emulsions and beverages comprising these complexes which slow the release of the caffeine. Also described are methods of preparing the complexes and emulsions and beverages comprising caffeine-tannic acid complexes.

Abstract: The present disclosure relates to colloids comprising caffeine-tannic acid complexes which slow the release of the caffeine. Also described are methods of preparing the colloids and beverages comprising colloids comprising caffeine-tannic acid complexes.

Abstract: A method for treating or preventing saccharide-related diseases or disorders, comprising administering a therapeutically or prophylactically effective amount of a polymer comprising at least one boronic acid group to a subject having or at risk of having a saccharide-related disease or disorder.

Abstract: Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: A power margin tracking control method and system for a multi-terminal high-voltage direct current converter station are provided. A power adjustment factor is introduced on the basis of a droop coefficient, to realize a self-adaptive regulation of a converter station operation mode to a real-time fluctuation of a wind and solar power. In this way, the system operation stability and the power fluctuation allocation capability in a grid-connected system are improved. Furthermore, a DC voltage deviation in the multi-terminal high-voltage direct current grid is reduced.

Abstract: The present disclosure provides a service life reminding system for a water bottle filter element. The service life reminding system for the water bottle filter element includes a one-way valve head, a mounting bracket, and a circuit board. The mounting bracket includes a first accommodating cavity. A portion of the one-way valve head is movably accommodated in the first accommodating cavity. A magnetic element is fixed in the mounting bracket. A magnetic sensor is arranged on the circuit board. Both of the circuit board and the magnetic sensor are accommodated in the one-way valve head. When the one-way valve head slides to abut against the mounting bracket, the magnetic sensor senses the magnetic element. When the one-way valve head slides away from the mounting bracket until the one-way valve head separates from the mounting bracket, the magnetic sensor is unable to sense the magnetic element.

Abstract: The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject. The mothed comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent.